
The acquisition brings Gallant’s experimental stem cell treatments for chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
synctest_0303_Changewebtitle
Web title is originally "synctest_0303_Changewebtitle original title when published to web initially"

